Bausch + Lomb Corporation (BLCO) Downgraded to Neutral by HC Wainwright & Co.

Market Context

Bausch + Lomb Corporation operates in the Healthcare sector. The stock currently trades at $20.03 with a market capitalization of $6.1B. The stock has gained 27.1% over the past 52 weeks.

Analyst downgrades can weigh on a stock in the short term as institutional investors who follow HC Wainwright & Co.'s research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Bausch + Lomb Corporation

Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Nov 02, 2026	HC Wainwright & Co.	Neutral	N/A
Oct 29, 2026	JP Morgan	Neutral	N/A
Oct 29, 2026	RBC Capital	Outperform	N/A
Oct 29, 2026	Citigroup	Buy	N/A
Oct 29, 2026	Wells Fargo	Equal-Weight	N/A

Related Tools: Analyst Ratings Dashboard | View BLCO Stock Page